Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET
-
Published:2024-06
Issue:6
Volume:35
Page:549-558
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Gennari A.ORCID, Brain E., De Censi A., Nanni O., Wuerstlein R., Frassoldati A., Cortes J., Rossi V., Palleschi M., Alberini J.L., Matteucci F., Piccardo A., Sacchetti G., Ilhan H., D’Avanzo F., Ruffilli B., Nardin S., Monti M., Puntoni M., Fontana V., Boni L., Harbeck N., Malagutti Bianca, Dib Bassam, Branni Carmen, D’Amico Mauro, Provinciali Nicoletta, Corradengo Davide, Fiz Francesco, Iacozzi Massimiliano, Rocca Andrea
Reference33 articles.
1. Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer;Robertson;Eur J Cancer,2018 2. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial;Robertson;Lancet,2016 3. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies;Saatci;J Mol Med,2021 4. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer;Gennari;Ann. Oncol,2021 5. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE);Johnston;J Clin Oncol,2020
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|